Cargando…

Hypoxia–Immune-Related Gene SLC19A1 Serves as a Potential Biomarker for Prognosis in Multiple Myeloma

BACKGROUND: Multiple myeloma (MM) remains an incurable malignant tumor of plasma cells. Increasing evidence has reported that hypoxia and immune status contribute to the progression of MM. In this research, the prognostic value of the hypoxia–immune-related gene SLC19A1 in MM was evaluated by bioinf...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Wenjin, Yuan, Peng, Liu, Weiqin, Xiao, Lichan, Xu, Chun, Mo, Qiuyu, Xu, Shujuan, He, Yuchan, Jiang, Duanfeng, Wang, Xiaotao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9358019/ https://www.ncbi.nlm.nih.gov/pubmed/35958555 http://dx.doi.org/10.3389/fimmu.2022.843369

Ejemplares similares

Immune-Associated Gene Signatures Serve as a Promising Biomarker of Immunotherapeutic Prognosis for Renal Clear Cell Carcinoma
por: Wang, Qi, et al.
Publicado: (2022)

A prognostic signature consisting of metabolism-related genes and SLC17A4 serves as a potential biomarker of immunotherapeutic prediction in prostate cancer
por: Li, He, et al.
Publicado: (2022)

Serum microRNA Profiles Serve as Novel Biomarkers for Autoimmune Diseases
por: Jin, Fangfang, et al.
Publicado: (2018)

Pyruvate dehydrogenase kinase 4‐mediated metabolic reprogramming is involved in rituximab resistance in diffuse large B‐cell lymphoma by affecting the expression of MS4A1/CD20
por: Jiang, Duanfeng, et al.
Publicado: (2021)

Kynurenine serves as useful biomarker in acute, Long- and Post-COVID-19 diagnostics
por: Bizjak, Daniel Alexander, et al.
Publicado: (2022)

Hypoxia-Related lncRNA Correlates With Prognosis and Immune Microenvironment in Lower-Grade Glioma
por: Xu, Shengchao, et al.
Publicado: (2021)

Therapeutic strategies to enhance immune response induced by multiple myeloma cells
por: Liu, Zhaoyun, et al.
Publicado: (2023)

SLC25A11 serves as a novel prognostic biomarker in liver cancer
por: Pan, Guoqiang, et al.
Publicado: (2020)

Multi-Omics Profiling Identifies Risk Hypoxia-Related Signatures for Ovarian Cancer Prognosis
por: Chen, Xingyu, et al.
Publicado: (2021)

An emerging prognosis prediction model for multiple myeloma: Hypoxia-immune related microenvironmental gene signature
por: Yu, Zhengyu, et al.
Publicado: (2022)

Efficacy Evaluation of Inflammatory Mediators in the Treatment of Multiple Myeloma with Daratumumab
por: Meng, Jie, et al.
Publicado: (2022)

PRICKLE1, a Wnt/PCP signaling component, is overexpressed and associated with inferior prognosis in acute myeloid leukemia
por: Jiang, Duanfeng, et al.
Publicado: (2021)

Four Prognosis-Associated lncRNAs Serve as Biomarkers in Ovarian Cancer
por: Zheng, Jianfeng, et al.
Publicado: (2021)

SLC7A2 serves as a potential biomarker and therapeutic target for ovarian cancer
por: Sun, Tianshui, et al.
Publicado: (2020)

SLC15A4 Serves as a Novel Prognostic Biomarker and Target for Lung Adenocarcinoma
por: Huang, Hui, et al.
Publicado: (2021)

Galectins can serve as biomarkers in COVID-19: A comprehensive systematic review and meta-analysis
por: Behnoush, Amir Hossein, et al.
Publicado: (2023)

The relevance between hypoxia-dependent spatial transcriptomics and the prognosis and efficacy of immunotherapy in claudin-low breast cancer
por: Sun, Huizhi, et al.
Publicado: (2023)

Prognosis of hyperviscosity syndrome in newly diagnosed multiple myeloma in modern-era therapy: A real-life study
por: Debureaux, Pierre-Edouard, et al.
Publicado: (2022)

Correlation of Cytokine Release Syndrome With Prognosis After Chimeric Antigen Receptor T Cell Therapy: Analysis of 54 Patients With Relapsed or Refractory Multiple Myeloma
por: Wang, Xue, et al.
Publicado: (2022)

Screening and Validation of the Hypoxia-Related Signature of Evaluating Tumor Immune Microenvironment and Predicting Prognosis in Gastric Cancer
por: Pei, Jun-Peng, et al.
Publicado: (2021)

Daratumumab for the Treatment of Multiple Myeloma
por: Plesner, Torben, et al.
Publicado: (2018)

Editorial: Immunotherapy in Multiple Myeloma
por: Giuliani, Nicola, et al.
Publicado: (2019)

Immunotherapy for the treatment of multiple myeloma
por: Boussi, Leora S., et al.
Publicado: (2022)

Epigenetic-related gene mutations serve as potential biomarkers for immune checkpoint inhibitors in microsatellite-stable colorectal cancer
por: Liu, Chao, et al.
Publicado: (2022)

Targeting SLC1A5 and SLC3A2/SLC7A5 as a Potential Strategy to Strengthen Anti-Tumor Immunity in the Tumor Microenvironment
por: Nachef, Marianna, et al.
Publicado: (2021)

LIGHT/TNFSF14 as a New Biomarker of Bone Disease in Multiple Myeloma Patients Experiencing Therapeutic Regimens
por: Brunetti, Giacomina, et al.
Publicado: (2018)

Follistatin-Like 3 Correlates With Lymph Node Metastasis and Serves as a Biomarker of Extracellular Matrix Remodeling in Colorectal Cancer
por: Yang, Chao, et al.
Publicado: (2021)

Aberrant metabolic processes promote the immunosuppressive microenvironment in multiple myeloma
por: Lv, Junqiang, et al.
Publicado: (2022)

Targeted Therapy With Immunoconjugates for Multiple Myeloma
por: Bruins, Wassilis S. C., et al.
Publicado: (2020)

Editorial: The Role of Microorganisms in Multiple Myeloma
por: Linares, Maria, et al.
Publicado: (2022)

SLC11A1 as a stratification indicator for immunotherapy or chemotherapy in patients with glioma
por: Xu, Houshi, et al.
Publicado: (2022)

Flow Cytometric Analysis of Bone Marrow Particle Cells for Measuring Minimal Residual Disease in Multiple Myeloma
por: Jiang, Duanfeng, et al.
Publicado: (2022)

ARID1A, ARID1B, and ARID2 Mutations Serve as Potential Biomarkers for Immune Checkpoint Blockade in Patients With Non-Small Cell Lung Cancer
por: Zhu, Guangsheng, et al.
Publicado: (2021)

Upregulation of lncRNA NR_046683 Serves as a Prognostic Biomarker and Potential Drug Target for Multiple Myeloma
por: Dong, Hang, et al.
Publicado: (2019)

Blood Levels of Co-inhibitory-Receptors: A Biomarker of Disease Prognosis in Multiple Sclerosis
por: Lavon, Iris, et al.
Publicado: (2019)

Classification of colon adenocarcinoma based on immunological characterizations: Implications for prognosis and immunotherapy
por: Xu, Midie, et al.
Publicado: (2022)

SKA1/2/3 serves as a biomarker for poor prognosis in human lung adenocarcinoma
por: Chen, Cheng, et al.
Publicado: (2020)

Laboratory Biomarkers for Diagnosis and Prognosis in COVID-19
por: Battaglini, Denise, et al.
Publicado: (2022)

Autoantibodies as biomarkers for breast cancer diagnosis and prognosis
por: Yang, Ruozhu, et al.
Publicado: (2022)

LncRNAs serve as novel biomarkers for diagnosis and prognosis of childhood ALL
por: Huang, Xuanmei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rgqcjid0rfsc3f8gpnqg25oi3m